More on PI3K Inhibitors as Senolytic Drugs
Senolytic drugs serve the purpose of selectively removing senescent cells from aging tissues. These drugs vary in effectiveness based on the stage of cellular senescence, the source of senescence, and the type of tissue involved. The future of clinical treatments may see a range of senolytic therapies tailored for specific age-related conditions. One intriguing application is the use of these drugs to target remaining senescent cancer cells post-chemotherapy. Research is underway on the potential of PI3K inhibitor drugs as senolytics in cancer cells, offering new dimensions for therapeutic exploration.
The targeted elimination of senescent cells induced by radiotherapy or chemotherapy through senolytic substances holds promise for reducing tumor relapse and treatment side effects. Studies have identified PI3K inhibitors like wortmannin and PX-866 as effective senolytics in senescent carcinoma cells. PX-866 has shown to induce apoptotic cell death in various cancer cell lines without affecting proliferating cells, offering insights into a potential application in combination cancer therapies. Further research into the senolytic properties of PI3K inhibitors opens new avenues for enhanced cancer treatment strategies.
Link: https://doi.org/10.1038/s41419-024-06755-x
